Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 12/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | UBE2M | P61081 | 6/20 | 0.34 |
| ▸ | DCUN1D1 | Q96GG9 | 6/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3768332 | 1.00 | CCR5 (0.42) | CCR5KCNH2EPHX1CTSSCTSK | |
| SCHEMBL3766272 | 0.78 | CCR5 (0.71) | CCR5KCNH2 | |
| SCHEMBL3762494 | 0.77 | CCR5 (0.56) | CCR5KCNH2UBE2MDCUN1D1 | |
| SCHEMBL3762498 | 0.77 | CCR5 (0.56) | CCR5KCNH2UBE2MDCUN1D1 | |
| SCHEMBL3758163 | 0.76 | EPHX1 (0.46) | KCNH2EPHX1CTSSCTSK | |
| SCHEMBL3758172 | 0.76 | EPHX1 (0.46) | KCNH2EPHX1CTSSCTSK | |
| SCHEMBL13052234 | 0.75 | KMT2A (0.43) | EPHX1CTSK | |
| SCHEMBL3752464 | 0.73 | UBE2M (0.40) | UBE2MDCUN1D1 | |
| SCHEMBL3822003 | 0.67 | CCR5 (0.41) | CCR5UBE2MDCUN1D1 | |
| SCHEMBL3758399 | 0.67 | MEN1 (0.44) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298366-A1 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| US-7790747-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| EP-1942890-A4 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORP (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20090099205-A1 | Chemokine receptor binding compounds | GENZYME CORPORATION | 2009-04-16 | — | — | US | disclosed |
| EP-1942890-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2008-07-16 | — | — | EP | disclosed |
| WO-2006138350-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298366-A1 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | CCR5, CXCR3, CCL5 | CCR5 1/4885KCNH2 4679/4885EPHX1 1384/4885 |
| US-20090099205-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | CCR5 1/4885KCNH2 4679/4885EPHX1 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.